Novo Nordisk A/S (NVO) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Novo Nordisk A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.301 -- 00:00:05.446 Good day and thank you for standing by. Welcome to the Q4 2025 Novo Nordisk 00:00:05.446 -- 00:00:09.930 Earnings Conference Call. At this time, all participants are in listen-only mode. 00:00:09.930 -- 00:00:13.213 After the speaker's presentation, there'll be a question and answer session. 00:00:13.213 -- 00:00:18.498 To ask a question during the session, you will need to press star 1 and 1 on your telephone. 00:00:18.498 -- 00:00:22.002 You will then hear an automated message advising your hand is raised. 00:00:22.002 -- 00:00:25.325 To withdraw your question, please press star 1 and 1 again. 00:00:25.325 -- 00:00:28.870 Please be advised that today's conference is being recorded. 00:00:28.870 -- 00:00:32.935 I would now like to hand the conference over to your first speaker today, Michael Novot, 00:00:32.935 -- 00:00:36.857 Head of Investor Relations. Please go ahead. 00:00:36.900 -- 00:00:41.005 Thank you very much, and welcome to this Novo Nordisk earnings call for the full year 00:00:41.005 -- 00:00:42.827 of 2025. 00:00:42.827 -- 00:00:46.872 My name is Michael Novot. I'm the Head of Investor Relations at Novo Nordisk. 00:00:46.872 -- 00:00:52.118 With me today I have CEO of Novo Nordisk, Mike Dustar, EVP Product 00:00:52.118 -- 00:00:57.625 and Portfolio Strategy, Ludovic Helfgott, EVP US Operations, Dave Moore, 00:00:57.625 -- 00:01:02.850 EVP Research and Development and Chief Scientific Officer, Martin Holtz-Lange, and Chief 00:01:02.850 -- 00:01:05.693 Financial Officer, Carsten Munch-Nusen. 00:01:05.693 -- 00:01:08.516 All speakers will be available for the Q&A session. 00:01:08.516 -- 00:01:13.681 Today's call is being webcasted live, and a recording will be made available on our website. 00:01:13.681 -- 00:01:18.444...